CN110302375A - A kind of glycoconjugate and application thereof - Google Patents
A kind of glycoconjugate and application thereof Download PDFInfo
- Publication number
- CN110302375A CN110302375A CN201910564902.0A CN201910564902A CN110302375A CN 110302375 A CN110302375 A CN 110302375A CN 201910564902 A CN201910564902 A CN 201910564902A CN 110302375 A CN110302375 A CN 110302375A
- Authority
- CN
- China
- Prior art keywords
- glycoconjugate
- polysaccharide
- protein
- preparation
- capsular polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a kind of glycoconjugates, and are aldehyde radical for the primary hydroxy group of bacterial eapsular polysaccharide and react the specific preparation method for preparing glycoconjugate and a kind of immunogenic composition comprising the glycoconjugate with the primary amino group of carrier protein lysine.The invention also discloses the glycoconjugate, immunogenic composition preparation prevention and/or treat individual streptococcus pneumoniae infection, disease relevant to streptococcus pneumonia drug or vaccine in application.Glycoconjugate of the present invention has the characteristics that immunogenicity is higher, bactericidal effect is stronger.
Description
Technical field
The present invention relates to vaccine development technical fields, and in particular to a kind of 4 type capsular polysaccharide of streptococcus pneumonia and carrier egg
White to react the glycoconjugate prepared, a kind of immunogenic composition comprising the glycoconjugate and the sugar are sewed
Object, immunogenic composition are closed in preparation prevention and/or treats individual streptococcus pneumoniae infection, disease relevant to streptococcus pneumonia
Application in the drug or vaccine of disease.
Background technique
Streptococcus pneumonia is gram-positive bacteria, and thallus is like spearhead shape, diplococcus in pairs or at short catenation, wide end
Relatively, tip is opposite, there is thicker pod membrane.It is worldwide to lead to morbidity and mortality that streptococcus pneumoniae infection, which causes a disease,
One of principal element.Pneumonia, heat generation bacteremia and meningitis are the most common performances of aggressive pneumococcal disease, and
Bacterium is disseminated in respiratory tract can lead to middle ear infection, nasosinusitis or relapsing bronchitis.
Capsular polysaccharide ingredient and structure outside pneumococcal cell wall is usually related with the pathogenicity of bacterium and serotype,
The variation of presently found streptococcus pneumoniae capsular polysaccharide has kind of the different serotype more than 90, wherein more than 20 kinds are used for
The vaccine of disease caused by preparing by streptococcus pneumoniae infection.Pneumococcal conjugates vaccine (PCV) is for preventing pneumonia
The Pnu-Imune 23 of streptococcus associated diseases can obtain ten trivalent vaccines on the whole world at present
Although capsular polysaccharide itself is immunogenicity, the conjugation of polysaccharide and carrier protein has been used for improving immunogene
Property, using the polysaccharide preparation polysaccharide protein conjugate vaccine connecting with protein carrier, the chemical bond of polysaccharide and protein carrier can be lured
Immune response of the guide pin to the bacterium for showing the polysaccharide that vaccine is included on the surface thereof, thus prevents disease, therefore, using next
Vaccine inoculation from the polysaccharide of pathogenic bacteria is the potential strategy for enhancing host immunity.Such as:
Non-patent literature Deciphering Antigenic Determinants of Streptococcus
pneumonia Serotype 4 Capsular Polysaccharide using Synthetic Oligosaccharides
It is that 4 pod membrane of S. pneumoniae serotypes is more that (ACS Chem.Biol., 2016,11 (2), pp 335-344), which discloses acetone acidic group,
The conservative antigen site of sugar.Meanwhile patent CN101180079A discloses the preparation method of vaccine, including Streptococcus pneumoniae serotype
4 polysaccharide of type is hydrolyzed by weak acid, removes part acetone acid protecting group, obtains facing an aldehyde radical by sodium periodate oxidation, then with egg
White conjugation obtains polysaccharide protein conjugate.The vaccine of this method preparation achieves very well in immune response and functional activity
Effect, but the method for sodium periodate oxidation sugar chain necessarily require in sugar chain have 2 adjacent free hydroxyl radicals, together
When, space that immunogenicity, yield, bactericidal effect of capsular polysaccharide etc. are still improved.
Patent CN108524931A, which discloses activation capsular polysaccharide and reacts with carrier protein, prepares glycoconjugate, specifically
, the capsular polysaccharide is streptococcus pneumonia (S.pneumoniae) (Pn)-serotype 3,10A, 12F and 33F capsular polysaccharide,
And the stability of the glycoconjugate, immunogenicity degree are verified.But the patent is general refers to immune
Can also include in Immunogenic Compositions by S. pneumoniae serotypes 1,4,5,6A, 6B, 7F, 8,9V, 11A, 14,15B, 18C,
The glycoconjugate of 19A, 19F, 22F and 23F capsular polysaccharide preparation, there is no open 4 capsular polysaccharide of S. pneumoniae serotypes with
The glycoconjugate of protein carrier coupling, more without disclosing the oxidation site when activation of 4 capsular polysaccharide of serotype.
Summary of the invention
Based on the defect of the above-mentioned prior art, the present invention provides a kind of streptococcus pneumonia blood with multiple active sites
The glycoconjugate of clear 4 capsular polysaccharide of type and protein carrier coupling, and disclose the activation of 4 capsular polysaccharide of S. pneumoniae serotypes
Oxidation site, the oxidation site includes acetylamino pyranoid form mannose group (β-D-ManpNAc), acetylamino pyrans
Type galactosyl (α-D-GalpNAc) and/or galactopyranose base (α-D-Galp).The present invention also provides a kind of sugar conjugations
The preparation method of object, this method are suitable for any polysaccharide comprising primary hydroxyl, this is an advantage over the obvious of periodate oxidation method
Advantage, sodium periodate oxidation method are needed with two adjacent (i.e. ortho position) free hydroxyl group (- OH) groups in sugar chain, and
The method for oxidation that the present invention uses only requires that capsular polysaccharide contains primary hydroxyl.It include the sugar invention further provides one kind
The immunogenic composition of conjugate.It is pre- in preparation that the present invention also provides the glycoconjugate, the immunogenic compositions
The individual streptococcus pneumoniae infection of anti-and/or treatment, the drug of disease relevant to streptococcus pneumonia or the application in vaccine.
Glycoconjugate of the present invention in the prior art with after periodate oxidation connect protein carrier conjugate
It compares, immunogenicity is higher, and bactericidal effect is significantly enhanced.
Specifically, the first aspect of the present invention, provides a kind of glycoconjugate, and the glycoconjugate is by bacterial capsule
The primary hydroxy group of polysaccharide, which reacts for aldehyde radical with the primary lysine amino groups of carrier protein, to be prepared, wherein the bacterium pod
Film polysaccharide is 4 type capsular polysaccharide of streptococcus pneumonia, and the primary hydroxy group of 4 type capsular polysaccharide of streptococcus pneumonia is the oxidation position of aldehyde radical
Point includes β-D-ManpNAc, α-D-GalpNAc and/or α-D-Galp.
Preferably, the 4 type capsular polysaccharide of streptococcus pneumonia can be natural or synthetic.
Preferably, the carrier protein contains one or more primary amino groups.The carrier protein can be from target
Mark GAP-associated protein GAP antigen of the enhancing to the specific immune response of the pathogen of pathogen, or mainly as adjuvant or general
The general immunogenic protein of immune response stimulant.
It is further preferred that the carrier protein is selected from CRM197, tetanus toxoid, derived from Gram-negative bacteria
Outer membrane protein, haemophilus influenzae surface lipoprotein (HiD), by haemophilus influenzae HiD protein gene and the bloodthirsty bar of influenza
Fusion protein that bacterium Hin47 protein gene is formed in a manner of 1:1, pertussis toxin/toxoid, hepatitis B surface antibody, second
Type hepatitis core antigen, rotavirus VP 7 protein or respiratory syncystial virus F and G-protein or its active part.
In the specific embodiment of the present invention, the carrier protein is CRM197.
Preferably, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.3 to 3.
It is further preferred that the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8 to 1.7.
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 1.0
To 1.4.
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8-
1.2。
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8-
1.0。
Preferably, every 10 to 50 sugared repetitive units of the bacterial eapsular polysaccharide, the carrier protein with it is described
There are at least one covalent bonds between bacterial eapsular polysaccharide.
The second aspect of the present invention provides a kind of preparation method of glycoconjugate, comprising:
Using nitroxyl compound and oxidant as activator by the primary hydroxy group of bacterial eapsular polysaccharide as aldehyde radical；
Bacterial eapsular polysaccharide containing aldehyde radical is reacted with the primary lysine amino groups of carrier protein and prepares glycoconjugate；
Wherein, the bacterial eapsular polysaccharide is 4 type capsular polysaccharide of streptococcus pneumonia, 4 type capsular polysaccharide of streptococcus pneumonia
Primary hydroxy group be aldehyde radical oxidation site include β-D-ManpNAc, α-D-GalpNAc and/or α-D-Galp.
Preferably, the molar ratio of the nitroxyl compound and capsular polysaccharide=(0.02~0.1): 1.
It is further preferred that the molar ratio of the nitroxyl compound and capsular polysaccharide=(0.06~0.08): 1.
Preferably, the molar ratio of the oxidant and capsular polysaccharide=(0.1~5): 1.
It is further preferred that the molar ratio of the oxidant and capsular polysaccharide=(1.8~2.5): 1.
Preferably, unreacted aldehyde radical is reduced in capping after being conjugated with carrier protein using sodium borohydride
Thus primary alconol makes in the modification step for being related to oxidation and subsequent conjugation, sugared epitope degree of modification is to minimize.
Preferably, the nitroxyl compound is with selective oxidation primary hydroxyl in the presence of the oxidant to produce
The ability of raw aldehyde radical.
Preferably, the oxidant is with selective oxidation primary hydroxyl in the presence of nitroxyl compound to generate aldehyde
The oxidant halogenated with N of the ability of base.
Preferably, the carrier protein contains one or more primary amino groups.The carrier protein can be from target
Mark GAP-associated protein GAP antigen of the enhancing to the specific immune response of the pathogen of pathogen, or mainly as adjuvant or general
The general immunogenic protein of immune response stimulant.
It is further preferred that the carrier protein is selected from CRM197, tetanus toxoid, derived from Gram-negative bacteria
Outer membrane protein, haemophilus influenzae surface lipoprotein (HiD), by haemophilus influenzae HiD protein gene and the bloodthirsty bar of influenza
Fusion protein that bacterium Hin47 protein gene is formed in a manner of 1:1, pertussis toxin/toxoid, hepatitis B surface antibody, second
Type hepatitis core antigen, rotavirus VP 7 protein or respiratory syncystial virus F and G-protein or its active part.
In the specific embodiment of the present invention, the carrier protein is CRM197.
Preferably, the 4 type capsular polysaccharide of streptococcus pneumonia can be natural or synthetic.
Preferably, the nitroxyl compound be 2,2,6,6- tetramethyl -1- piperidines oxygroup free radicals (TEMPO) or its
Derivative.
It is further preferred that the TEMPO or derivatives thereof is selected from: TEMPO, 2, the oxidation of 2,6,6- tetramethyl piperidines
Object, 2,2,6,6- tetramethyl -4- (sulfonyloxy methyl oxygroup) -1- piperidines oxygroup, 4- phosphonato-TEMPO, 4- oxo-TEMPO,
4- isothiocyanic acid base-TEMPO, 4- (2- iodacetyl amino)-TEMPO free radical, 4- hydroxyl-TEMPO, 4- acetylaminohydroxyphenylarsonic acid 2,2,
6,6- tetramethyl piperidine 1- oxygroup, 4- cyano-TEMPO, 4- methoxyl group-TEMPO, 4- carboxyl-TEMPO, 4- (2- acetyl bromide ammonia
Base)-TEMPO or 4- amino-TEMPO.
In the specific embodiment of the present invention, the nitroxyl compound is TEMPO.
Preferably, the molar ratio of the TEMPO and capsular polysaccharide=(0.02~0.1): 1.
It is further preferred that the molar ratio of the TEMPO and capsular polysaccharide=(0.06~0.08): 1.
Preferably, the oxidant is the oxidant halogenated with N.It is further preferred that the oxidant is selected from: N-
Chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, the chloro- 1,3,5- triazine -2,4,6- of 1,3,5- tri-
Triketone, the bromo- 1,3,5- triazine -2,4,6- triketone of 1,3,5- tri- or the iodo- 1,3,5- triazine -2,4,6- triketone of 1,3,5- tri-.
In the specific embodiment of the present invention, the oxidant is N-iodosuccinimide (NIS).
Preferably, the molar ratio of NIS and capsular polysaccharide=(0.1~5): 1.
It is further preferred that the molar ratio of the NIS and capsular polysaccharide=(1.8~2.5): 1.
Preferably, the primary hydroxy group must react for aldehyde radical is carried out in aqueous solvent or aprotic solvent.
It is furthermore preferred that the aqueous solvent or aprotic solvent are selected from n-methyl-2-pyrrolidone (NMP), DMSO (two
First sulfoxide), sulfolane, dimethyl acetamide (DMA), hexamethyl phosphoramide (HMPA) or DMF (dimethylformamide).
Preferably, the nitroxyl compound is used with catalytic amount≤0.1 molar equivalent, and used by change
The amount of oxidant realizes the oxidizability of desired capsular polysaccharide.
Preferably, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.3 to 3.
It is further preferred that the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8 to 1.7.
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 1.0
To 1.4.
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8-
1.2。
In the specific embodiment of the present invention, the mass ratio of the bacterial eapsular polysaccharide and carrier protein is 0.8-
1.0。
Preferably, every 10 to 50 sugared repetitive units of the bacterial eapsular polysaccharide, the carrier protein with it is described
There are at least one covalent bonds between bacterial eapsular polysaccharide.
Preferably, the time of the oxidation is 1-4h.
In the specific embodiment of the present invention, the oxidization time is 2-4h.
In the specific embodiment of the present invention, the preparation method of the glycoconjugate, comprising:
1) 4 type capsular polysaccharide of streptococcus pneumonia is hydrolyzed into the molecular weight of 50-900kDa, using TEMPO and NIS as activation
Agent is by the primary hydroxy group of β-D-ManpNAc, the α-D-GalpNAc of 4 type capsular polysaccharide of streptococcus pneumonia and the site α-D-Galp
For aldehyde radical, the 4 type capsular polysaccharide of streptococcus pneumonia of activation is obtained；Preferably, the 4 type pod membrane of streptococcus pneumonia of the activation is more
The oxidizability of sugar is 10-30, it is further preferred that the oxidizability of the 4 type capsular polysaccharide of streptococcus pneumonia of the activation is 12-
20, still more preferably, the oxidizability of the 4 type capsular polysaccharide of streptococcus pneumonia of the activation is 13-18.Preferably, institute
The priming reaction time stated is 1-5h.It is further preferred that the priming reaction time is 2-3h.
2) the 4 type capsular polysaccharide of streptococcus pneumonia of step 1) activation preparation is reacted with the primary lysine amino groups of CRM197 to obtain
Obtain glycoconjugate.Wherein, unreacted aldehyde radical is restored in capping after being conjugated with carrier protein using sodium borohydride
For primary alconol.
3) purification step 2) obtain glycoconjugate.
Preferably, 4 type capsular polysaccharide of streptococcus pneumonia is hydrolyzed into the molecular weight of 300-890kDa in the step 1).
Preferably, the step 1) further includes the steps that purifying activated 4 type capsular polysaccharide of streptococcus pneumonia.
Preferably, the temperature of capping is 20-50 DEG C in the step 2).
Preferably, the capping time is 20-60h in the step 2).
The third aspect of the present invention provides immunogenic composition, is conjugated comprising sugar described in first aspect present invention
The glycoconjugate and pharmaceutically acceptable excipient, carrier of the preparation of preparation method described in object or second aspect of the present invention
And/or diluent.
Preferably, the immunogenic composition also includes the glycoconjugate of other bacterial eapsular polysaccharides, described its
His bacterial eapsular polysaccharide be selected from S. pneumoniae serotypes 1,3,3F, 5,6A, 6B, 7F, 8,9V, 10A, 11A, 12F, 14,15B,
18C, 19A, 19F, 22F, 23F, 33F capsular polysaccharide.
Preferably, the dosage form of the immunogenic composition is selected from: tablet, pill, injection, inhalant, contains capsule
Piece, suppository, emulsion, microemulsion, sub-micellar emulsion, nano particle, gelling agent, pulvis, suspended emulsion, cream, jelly, spray
Deng.
Preferably, the administration mode of the immunogenic composition is selected from: oral, enteral administration, subcutaneous injection, muscle note
It penetrates, be injected intravenously, administration, eye socket administration, retrobulbar administration, view in nasal-cavity administration, cutaneous penetration, sub-conjunctival administration, eyeball
Film administration, choroid administration, intrathecal injection etc..
Preferably, the immunogenic composition further includes adjuvant.It is furthermore preferred that the adjuvant is aluminium system adjuvant.
Most preferably, aluminium system adjuvant is selected from aluminum phosphate, aluminum sulfate and aluminium hydroxide.
The fourth aspect of the present invention provides glycoconjugate described in first aspect present invention, second aspect of the present invention institute
State preparation method preparation glycoconjugate or third aspect present invention described in immunogenic composition preparation prevention and/or
Treat individual streptococcus pneumoniae infection, the drug of disease relevant to streptococcus pneumonia or the application in vaccine.
Glycoconjugate provided by the invention, immunogenic composition immunogenicity with higher, and induced in individual
Therapeutic immunization response.
Preferably, the disease relevant to streptococcus pneumonia be selected from pneumonia, meningitis, cellulitis, osteomyelitis,
Endocarditis, septic shock, heat generation bacteremia, middle ear infection, nasosinusitis, relapsing bronchitis and other serious invade
Attacking property disease.
The fifth aspect of the present invention provides a kind of prevention and/or the individual streptococcus pneumoniae infection for the treatment of and pneumonia streptococcus
The drug of the relevant disease of bacterium, the drug include glycoconjugate or immunogenic composition of the present invention.
The sixth aspect of the present invention provides a kind of prevention and/or the individual streptococcus pneumoniae infection for the treatment of and pneumonia streptococcus
The vaccine of the relevant disease of bacterium, the vaccine include glycoconjugate or immunogenic composition of the present invention.
The seventh aspect of the present invention provides a kind of prevention and/or the individual streptococcus pneumoniae infection for the treatment of and pneumonia streptococcus
The method of the relevant disease of bacterium, the method include applying the glycoconjugate of the present invention of effective dose to individual or exempting from
Epidemic disease Immunogenic Compositions.
" glycoconjugate " of the present invention refers to the sugar being covalently conjugated with carrier protein.Wherein, the glycoconjugate
In may include a certain amount of free sugar.
" oxidizability " of the present invention refers to the sugared repetitive unit molar ratio of every mole of aldehyde.
It is of the present invention " pharmaceutically acceptable " to refer to neither significant stimulation individual nor inhibit applied product
Active material biological activity and characteristic.
" prevention " of the present invention, which refers to by applying product of the present invention, to be inhibited symptom or delays specific
All behaviors of symptom anxiety.
" treatment " of the present invention refers to sign, the symptom for improving disease or pathological state after disease has started development
Etc. therapy intervention.
" individual " of the present invention includes mammal and people.
" effective dose " of the present invention refers to be provided after with single or multiple doses to individual or organ
The amount or dosage of the composition of the invention of desired treatment or prevention.
"and/or" of the present invention includes selecting the project and any amount of projects combo that one lists.
" comprising " of the present invention is open description, containing described specified ingredient or step, and will not
Other the specified ingredients or step substantially influenced.
Detailed description of the invention
Hereinafter, carrying out the embodiment that the present invention will be described in detail in conjunction with attached drawing, in which:
Fig. 1: figure A, B respectively indicate the structural formula and expression formula of the capsular polysaccharide of S. pneumoniae serotypes 4, wherein figure A
In 3 ellipse circled positions indicate the oxidation site by TEMPO/NIS oxidation capsular polysaccharide, respectively β-D-ManpNAc, α-D-
GalpNAc and α-D-Galp, the position that arrow is directed toward indicate the site for the oxidation that periodate mediates, specially α-D-Galp.
Fig. 2: using periodate oxidation relative to the S. pneumoniae serotypes 4- for using TEMPO/NIS oxidation prepared
The yield of CRM197 glycoconjugate compares.
Fig. 3: using periodate oxidation relative to the S. pneumoniae serotypes 4- for using TEMPO/NIS oxidation prepared
The immunogenicity of CRM197 glycoconjugate compares.
Fig. 4: using periodate oxidation relative to the S. pneumoniae serotypes 4- for using TEMPO/NIS oxidation prepared
The bactericidal effect of CRM197 glycoconjugate is compared.
Fig. 5: activation capsular polysaccharide, conjugate and the work generated by TEMPO/NIS oxidation generated by periodate oxidation
Change the comparison of the nuclear-magnetism structure of capsular polysaccharide, conjugate, wherein F4 is 4 capsular polysaccharide of S. pneumoniae serotypes.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description, it is clear that described embodiment is only section Example of the invention, rather than all.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
The purchase producer of agents useful for same and formula in the specific embodiment of the invention:
TEMPO:2,2,6,6- tetramethyl piperidine oxides, Sinopharm Chemical Reagent Co., Ltd.；
NIS:N- Iodosuccinimide, Sinopharm Chemical Reagent Co., Ltd.；
Rabbit: Beijing North Sheng Yan biological products Co., Ltd, common rabbit, 2.5kg or so；
4 capsular polysaccharide of serotype: Kang Xinuo biology joint-stock company self-control；
CRM197 carrier protein: Kang Xinuo biology joint-stock company self-control；
Periodate: Tianjin Kermel Chemical Reagent Co., Ltd., purity 99.0%；
NMR: Brooker (Beijing) Science and Technology Ltd., 600MHz；
Investment company, Pfizer, import drugs registration certificate number: S20160042.
Embodiment 1 aoxidizes the S. pneumoniae serotypes 4-CRM197 glycoconjugate system of capsular polysaccharide using TEMPO/NIS
It is standby
In order to improve the yield of serotype 4-CRM197 glycoconjugate, certainly using 2,2,6,6- tetramethyl -1- piperidines oxygroups
N-iodosuccinimide (NIS) by base (TEMPO) and as co-oxidants by oxidation of primary alcohols at aldehyde radical, and with carrier egg
White primary lysine amino groups reaction, prepares serotype 4-CRM197 glycoconjugate.NMR is analysis shows oxidation site and high iodine
The site for the oxidation that hydrochlorate mediates is different.In the case where TEMPO-NIS oxidation, oxidation site is β-D-ManpNAc, α-D-
GalpNAc and α-D-Galp (see the ellipse encircled portion of Figure 1A), and when using periodate, α-D-Galp is main oxidation position
Point (see Figure 1A arrow locations).
The step of preparing serotype 4-CRM197 glycoconjugate is as follows:
(1) 4 capsular polysaccharide of serotype is hydrolyzed into the molecular weight of 50kDa to 900kDa using heating under acid condition；
(2) 4 capsular polysaccharide of TEMPO/NIS activated serotype is used, specifically: 4 capsular polysaccharide polysaccharide concentration of 2g/L serotype,
Final concentration of 0.25M NaHCO3/0.025M Na2CO30.08Meq TEMPO is added in pH8.6 carbonate buffer solution, adds by table 1
Enter NIS, be protected from light magnetic agitation, room temperature carries out priming reaction 2 hours.
The amount of TEMPO and NIS that table 1 is added
50kD film packet, purified water ultrafiltration.Anthrone method surveys sugared content, and MBTH method surveys aldehyde group content, and TSK surveys molecular weight, nuclear-magnetism
Detect capsular polysaccharide structure.
(3) by 4 capsular polysaccharide of the serotype of activation and CRM197 carrier protein conjugation reaction:
CRM197 carrier protein is added in capsular polysaccharide reaction density 10-20g/L, mixes, and 0.5-2g/L cyano boron hydrogen is added
Change sodium, is protected from light, 37 DEG C of reaction 48h.Wherein, sodium borohydride is added to reaction density 0.5g/L, reacts 1-3h.
(4) conjugate for obtaining step (3) purifies:
100kD film packet, 0.9%NaCl ultrafiltration 40 times.
(5) analyte detection is conjugated:
Anthrone method surveys capsular polysaccharide content, and Lowry method surveys protein content, and the DOC precipitation method survey dissociation amylase content, SDS-
PAGE method surveys Free protein content, and CL-4B measures KD。
Wherein, it using the capsular polysaccharide formation condition of TEMPO/NIS oxidation and multiple serotype 4-CRM197 is characterized is conjugated
Object, concrete outcome are shown in Table 2:
The capsular polysaccharide formation condition and characterization situation of 2 TEMPO/NIS of table oxidation
Embodiment 2 uses the immunogenicity of the S. pneumoniae serotypes 4-CRM197 conjugate of TEMPO/NIS oxidizing process
Test group serotype 4- is prepared according to the step of preparing serotype 4-CRM197 glycoconjugate described in embodiment 1
CRM197 conjugate, and the application effect of conjugate is verified, zoopery uses, common rabbit, 2.5kg or so, half male and half female,
Experiment sets 10 groups altogether, 8 groups of experimental groups, 1 group of positive control, 1 group of negative control, every group of 4 rabbit, subcutaneous injection, respectively at 0,
14, it is immunized within 28 days, injection dosage, which is behaved, uses half dosage, and 42 days Jugular vessels acquire 4 DEG C of conditions of whole blood after being immunized
Lower 8000rpm is centrifuged 6min, separates serum, is placed in -80 DEG C of preservations, and specific group of testing is shown in Table 3:
Elisa method: 4 type capsular polysaccharides are diluted to corresponding peridium concentration with coating buffer, every hole adds in 96 orifice plates
Entering 100 microlitres, 2~8 DEG C of coatings are stayed overnight, abandoning coating buffer, and board-washing 1 time, addition test serum, (20~25 DEG C) incubation 1h of room temperature,
Board-washing 5 times, the sheep anti-mouse igg of the diluted alkali phosphatase enzyme mark of 100 microlitres/hole 1:5000 is added, is incubated at room temperature 1h, board-washing 5
It is secondary, 100 microlitres/hole of developing solution is added, is protected from light colour developing 30min, 50 microlitres/hole of terminate liquid is added, takes out extinction in 405nm wavelength
Angle value.
The different method for oxidation of table 3 prepare the test group of conjugate
Sodium metaperiodate test group is using 4 capsular polysaccharide of sodium periodate oxidation S. pneumoniae serotypes and prepares conjugate
Method is that 4 capsular polysaccharide of S. pneumoniae serotypes is hydrolyzed by weak acid, part acetone acid protecting group is removed, by sodium metaperiodate
Oxidation obtains ortho position aldehyde radical, then is conjugated with albumen, obtains polysaccharide protein conjugate (referring specifically to patent CN101180079A).
Opsonophagocytosis activity of the serotype 4-CRM197 conjugate in rabbit is measured in rabbit at the standard conditions
(OPA) potency.Compared with the conjugate generated by periodate oxidation, by conjugate (the batch TEMPO- of TEMPO/NIS generation
1, TEMPO-2, TEMPO-3, TEMPO-4 respectively referring in table 2 to the characterize data of F4-1, F4-3, F4-4, F4-5 conjugate)
Yield is higher (referring to fig. 2), and immunogenicity is higher (referring to Fig. 3), and bactericidal effect significantly increases (referring to fig. 4).Wherein, by
The glycoconjugate yield that TEMPO/NIS generates 4 batches is respectively 55%, 60%, 62%, 57%, maximum output 62%.
TEMPO/NIS test group is more considerably higher than the immunogenicity of periodate test group, bactericidal effect, and difference has conspicuousness.
3 nuclear-magnetism structure of embodiment compares
Activation capsular polysaccharide, conjugate and the activation pod generated by TEMPO/NIS oxidation generated by periodate oxidation
The comparison (referring to Fig. 5) of the nuclear-magnetism structure of film polysaccharide, conjugate shows that generation streptococcus pneumonia 4 is aoxidized by TEMPO/NIS to be activated
Capsular polysaccharide structure and purified capsular polysaccharide structure are closer in capsular polysaccharide, conjugate, no significant difference, conservative antigen α-D-
2,3 acetone acidic groups carry out integral area statistics, calculating mole to anomeric proton and acetone acid methyl without significant change in Galp
Than specific data are referring to table 4, the results showed that the activation capsular polysaccharide pyruvic acid protecting group that TEMPO/NIS oxidation generates obtains
Retain very well.
The different method for oxidation of table 4 obtain activated polysaccharide acetone acid methyl and anomeric proton molar ratio
| Title | Acetone acid methyl and anomeric proton molar ratio |
| F4TEMPO method oxidation gained activated polysaccharide | 4.59 |
| F4 sodium periodate method oxidation gained activated polysaccharide | 1.43 |
The preferred embodiment of the present invention has been described above in detail, still, during present invention is not limited to the embodiments described above
Detail within the scope of the technical concept of the present invention can be with various simple variants of the technical solution of the present invention are made, this
A little simple variants all belong to the scope of protection of the present invention.
It is further to note that specific technical features described in the above specific embodiments, in not lance
In the case where shield, can be combined in any appropriate way, in order to avoid unnecessary repetition, the present invention to it is various can
No further explanation will be given for the combination of energy.
Claims (12)
1. a kind of glycoconjugate, which is characterized in that it is aldehyde that the glycoconjugate, which is by the primary hydroxy group of bacterial eapsular polysaccharide,
Base is reacted with the primary lysine amino groups of carrier protein to be prepared, wherein the bacterial eapsular polysaccharide is 4 type of streptococcus pneumonia
Capsular polysaccharide, the primary hydroxy group of 4 type capsular polysaccharide of streptococcus pneumonia are that the oxidation site of aldehyde radical includes β-D-ManpNAc, α-
D-GalpNAc and/or α-D-Galp.
2. glycoconjugate according to claim 1, which is characterized in that the carrier protein is selected from CRM197, tetanus
Toxoid, the outer membrane protein derived from Gram-negative bacteria, haemophilus influenzae surface lipoprotein (HiD), by the bloodthirsty bar of influenza
Fusion protein, the pertussis toxin/class that bacterium HiD protein gene and haemophilus influenzae Hin47 protein gene are formed in a manner of 1:1
Toxin, hepatitis B surface antibody, hepatitis B core antigen, rotavirus VP 7 protein or respiratory syncystial virus F and G
Albumen or its active part.
3. glycoconjugate according to claim 1 or 2, which is characterized in that the bacterial eapsular polysaccharide and carrier protein
Mass ratio be 0.3 to 3.
4. glycoconjugate according to claim 1 to 3, which is characterized in that every the 10 of the bacterial eapsular polysaccharide to
50 sugared repetitive units, there are at least one covalent bonds between the carrier protein and the bacterial eapsular polysaccharide.
5. a kind of preparation method of glycoconjugate characterized by comprising
Using nitroxyl compound and oxidant as activator by the primary hydroxy group of bacterial eapsular polysaccharide as aldehyde radical；
Bacterial eapsular polysaccharide containing aldehyde radical is reacted with the primary lysine amino groups of carrier protein and prepares glycoconjugate；
Wherein, the bacterial eapsular polysaccharide be 4 type capsular polysaccharide of streptococcus pneumonia, the primary of 4 type capsular polysaccharide of streptococcus pneumonia
The oxidation site that hydroxyl is oxidized to aldehyde radical includes β-D-ManpNAc, α-D-GalpNAc and/or α-D-Galp.
6. a kind of preparation method of glycoconjugate according to claim 5, which is characterized in that the nitroxyl compound
For 2,2,6,6- tetramethyl -1- piperidines oxygroup free radical or derivatives thereof.
7. a kind of preparation method of glycoconjugate according to claim 5 or 6, which is characterized in that the oxidant is
N-iodosuccinimide.
8. according to a kind of preparation method of any glycoconjugate of claim 5-7, which is characterized in that the carrier egg
It is white to be selected from CRM197, tetanus toxoid, the outer membrane protein derived from Gram-negative bacteria, haemophilus influenzae surface lipoprotein
(HiD), the fusion formed in a manner of 1:1 by haemophilus influenzae HiD protein gene and haemophilus influenzae Hin47 protein gene
Albumen, pertussis toxin/toxoid, hepatitis B surface antibody, hepatitis B core antigen, rotavirus VP 7 protein or
Respiratory syncystial virus F and G-protein or its active part.
9. according to a kind of preparation method of any glycoconjugate of claim 5-8, which is characterized in that the bacterium pod
The mass ratio of film polysaccharide and carrier protein is 0.3 to 3.
10. immunogenic composition, which is characterized in that include claim the 1-4 any glycoconjugate or claim
The glycoconjugate and pharmaceutically acceptable excipient, carrier and/or diluent of any preparation method preparation of 5-9.
11. immunogenic composition according to claim 10, which is characterized in that the immunogenic composition also wraps
Glycoconjugate containing other bacterial eapsular polysaccharides, other described bacterial eapsular polysaccharides be selected from S. pneumoniae serotypes 1,3,
3F, 5,6A, 6B, 7F, 8,9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 33F capsular polysaccharide.
12. the sugar of any preparation method preparation of any glycoconjugate of claim 1-4, claim 5-9 is sewed
Object or any immunogenic composition of claim 10-11 are closed in preparation prevention and/or treats individual streptococcus pneumonia
Infection, the drug of disease relevant to streptococcus pneumonia or the application in vaccine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910564902.0A CN110302375A (en) | 2019-06-27 | 2019-06-27 | A kind of glycoconjugate and application thereof |
| PCT/CN2020/087841 WO2020259076A1 (en) | 2019-06-27 | 2020-04-29 | Glycoconjugate and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910564902.0A CN110302375A (en) | 2019-06-27 | 2019-06-27 | A kind of glycoconjugate and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110302375A true CN110302375A (en) | 2019-10-08 |
Family
ID=68076299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910564902.0A Pending CN110302375A (en) | 2019-06-27 | 2019-06-27 | A kind of glycoconjugate and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110302375A (en) |
| WO (1) | WO2020259076A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110804097A (en) * | 2019-10-30 | 2020-02-18 | 云南沃森生物技术股份有限公司 | Method for simultaneously preparing two monoclonal antibodies |
| WO2020259076A1 (en) * | 2019-06-27 | 2020-12-30 | 康希诺生物股份公司 | Glycoconjugate and use thereof |
| US11116828B2 (en) | 2017-12-06 | 2021-09-14 | Merck Sharp & Dohme Corp. | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2023025003A1 (en) * | 2021-08-27 | 2023-03-02 | 康希诺生物股份公司 | Method for preparing pneumococcal-binding vaccine |
| WO2023025002A1 (en) * | 2021-08-27 | 2023-03-02 | 康希诺生物股份公司 | Streptococcus pneumoniae conjugate vaccine composition |
| US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110381A1 (en) * | 2005-04-08 | 2006-10-19 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| WO2015144031A1 (en) * | 2014-03-26 | 2015-10-01 | 天津康希诺生物技术有限公司 | Pneumococcus polysaccharide protein conjugated vaccine and preparation method therefor |
| CN107427568A (en) * | 2015-01-15 | 2017-12-01 | 辉瑞公司 | For the immunogenic composition in Pnu-Imune 23 |
| CN108367063A (en) * | 2015-07-21 | 2018-08-03 | 辉瑞公司 | Include the immunogenic composition and its kit and purposes of conjugated Capsular saccharide antigen |
| CN108524931A (en) * | 2012-12-20 | 2018-09-14 | 辉瑞公司 | Glycoconjugate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018010920A (en) * | 2016-03-15 | 2019-03-06 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | Novel polysaccharide-protein conjugates and process to obtain thereof. |
| EP3474890A1 (en) * | 2016-06-22 | 2019-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. | Pneumococcal polysaccharide-protein conjugate composition |
| EA201990838A1 (en) * | 2016-09-30 | 2019-08-30 | Байолоджикал И Лимитед | COMPOSITIONS OF A POLYVALENT PNEUMOCOCCUS VACCINE CONTAINING POLYSACCHARIDE-PROTEIN CONJUGATES |
| CN110302375A (en) * | 2019-06-27 | 2019-10-08 | 康希诺生物股份公司 | A kind of glycoconjugate and application thereof |
-
2019
- 2019-06-27 CN CN201910564902.0A patent/CN110302375A/en active Pending
-
2020
- 2020-04-29 WO PCT/CN2020/087841 patent/WO2020259076A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110381A1 (en) * | 2005-04-08 | 2006-10-19 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN101180079A (en) * | 2005-04-08 | 2008-05-14 | 惠氏公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN108524931A (en) * | 2012-12-20 | 2018-09-14 | 辉瑞公司 | Glycoconjugate |
| WO2015144031A1 (en) * | 2014-03-26 | 2015-10-01 | 天津康希诺生物技术有限公司 | Pneumococcus polysaccharide protein conjugated vaccine and preparation method therefor |
| CN107427568A (en) * | 2015-01-15 | 2017-12-01 | 辉瑞公司 | For the immunogenic composition in Pnu-Imune 23 |
| CN108367063A (en) * | 2015-07-21 | 2018-08-03 | 辉瑞公司 | Include the immunogenic composition and its kit and purposes of conjugated Capsular saccharide antigen |
Non-Patent Citations (1)
| Title |
|---|
| C JONES ET AL.: "N.m.r. and conformational analysis of the capsular polysaccharide from Streptococcus pneumoniae type 4", 《CARBOHYDR RES》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116828B2 (en) | 2017-12-06 | 2021-09-14 | Merck Sharp & Dohme Corp. | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| US11850278B2 (en) | 2017-12-06 | 2023-12-26 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2020259076A1 (en) * | 2019-06-27 | 2020-12-30 | 康希诺生物股份公司 | Glycoconjugate and use thereof |
| CN110804097A (en) * | 2019-10-30 | 2020-02-18 | 云南沃森生物技术股份有限公司 | Method for simultaneously preparing two monoclonal antibodies |
| CN110804097B (en) * | 2019-10-30 | 2021-02-26 | 云南沃森生物技术股份有限公司 | Method for simultaneously preparing two monoclonal antibodies |
| WO2023025003A1 (en) * | 2021-08-27 | 2023-03-02 | 康希诺生物股份公司 | Method for preparing pneumococcal-binding vaccine |
| WO2023025002A1 (en) * | 2021-08-27 | 2023-03-02 | 康希诺生物股份公司 | Streptococcus pneumoniae conjugate vaccine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020259076A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110302375A (en) | A kind of glycoconjugate and application thereof | |
| Seeberger | Discovery of semi-and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach: focus review | |
| CN104870463B (en) | Sugared conjugation methods | |
| US9168313B2 (en) | Vaccine | |
| ES2621359T3 (en) | Modified polysaccharides for conjugate vaccines | |
| JP6808658B2 (en) | Multivalent pneumococcal conjugate vaccine | |
| CN108367063A (en) | Include the immunogenic composition and its kit and purposes of conjugated Capsular saccharide antigen | |
| JP2020533437A (en) | Its use in pneumococcal polysaccharides and immunogenic polysaccharides-carrier protein conjugates | |
| JP2020533442A (en) | Its use in pneumococcal polysaccharides and immunogenic polysaccharides-carrier protein conjugates | |
| Giebink et al. | Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media | |
| JP2020533439A (en) | Its use in pneumococcal polysaccharides and immunogenic polysaccharides-carrier protein conjugates | |
| CN103402544A (en) | Conjugation process | |
| JP4918356B2 (en) | Y group meningococcal vaccine and their meningococcal combination vaccine | |
| JP5237259B2 (en) | Type 5 and type 8 capsular polysaccharides of overproducing S. aureus strains | |
| WO2020009462A1 (en) | Multivalent immunogenic composition comprising polysaccharide-protein conjugates, and vaccine comprising same for preventing disease caused by streptococcus pneumoniae | |
| AU2018290298A1 (en) | Immunogenic compositions | |
| KR20200005458A (en) | Immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate, and phamatiutical composition comprising the same | |
| WO2023025002A1 (en) | Streptococcus pneumoniae conjugate vaccine composition | |
| WO2023025003A1 (en) | Method for preparing pneumococcal-binding vaccine | |
| US20210401960A1 (en) | Multivalent glycoconjugates immunogenic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |